Skip to main content
XNCR
NASDAQ Life Sciences

Xencor Q2 Results: Pipeline Progress, XmAb819 ESMO Spotlight, and XmAb541 Combo Pivot

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.84
Mkt Cap
$1.471B
52W Low
$6.92
52W High
$21.76
52W Position info
187% above low
Off High info
8.8% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

XNCR has more than doubled off its 52-week low of $6.92.

Summary

Xencor reported Q2 2026 financials alongside a pipeline update. The key clinical news: Phase 1 XmAb819 (ENPP3 x CD3) data in advanced ccRCC was accepted for an oral presentation at ESMO in October, with a registration-enabling study planned for 2027. The company is prioritizing the XmAb541/XmAb808 combination over monotherapy after seeing moderate activity and hearing-related toxicity at higher doses; monotherapy showed 14% ORR in ovarian and 28% in germ cell tumors. XmAb412, a XenLock bispecific, entered Phase 1. The update follows the recent $105M Alexion royalty resolution, which removed a financial overhang. No specific Q2 revenue or EPS figures were disclosed in the release, limiting immediate financial impact, but the pipeline catalysts are material for a $1.5B market cap biotech.

At the time of this announcement, XNCR was trading at $19.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $6.92 to $21.76. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

XNCR - Latest Insights

XNCR
Nov 04, 2026, 4:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $37.09 info
Change: +$1.09 (+3%) info
Market Cap: $2.783B info
XNCR
Nov 04, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $34.98
Real-time Price: $37.09 info
Change: +$2.12 (+6%) info
Market Cap: $2.783B info
XNCR
Oct 26, 2026, 1:00 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $30.18
Real-time Price: $37.09 info
Change: +$6.92 (+23%) info
Market Cap: $2.783B info
XNCR
Oct 26, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.02
Real-time Price: $37.09 info
Change: +$3.07 (+9%) info
Market Cap: $2.783B info
XNCR
Oct 25, 2026, 4:35 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.55
Real-time Price: $37.09 info
Change: +$11.54 (+45%) info
Market Cap: $2.783B info